Fatty liver (MASLD)

Resmetirom effects in MASH were similar across common risk genotypes

A pre-specified analysis of 738 MAESTRO-NASH patients found no significant effect of common MASH risk genotypes on resmetirom response, though the study was not powered for small effects.